TFRC and acute myeloid leukemia: Both TF1 (erythroleukemia, CD3-, CD13+, CD14-, CD15-, CD19-, CD33+, CD34+, CD71+, HLA-DR+) and ELF-153 (hypodiploid AML, CD3-, CD4+, CD13+, CD14-, CD15-, CD19-, CD33+, CD34+, HLA-DR+) displayed features of monocytic differentiation as demonstrated by a significant increase in CD14, CD36, CD64, and HLA-DR MFIs (Fig. S13).